IL279199B1 - EAAT2 activators and methods of using them - Google Patents
EAAT2 activators and methods of using themInfo
- Publication number
- IL279199B1 IL279199B1 IL279199A IL27919920A IL279199B1 IL 279199 B1 IL279199 B1 IL 279199B1 IL 279199 A IL279199 A IL 279199A IL 27919920 A IL27919920 A IL 27919920A IL 279199 B1 IL279199 B1 IL 279199B1
- Authority
- IL
- Israel
- Prior art keywords
- methods
- eaat2
- activators
- eaat2 activators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680423P | 2018-06-04 | 2018-06-04 | |
| US201862680418P | 2018-06-04 | 2018-06-04 | |
| PCT/US2019/035452 WO2019236625A1 (en) | 2018-06-04 | 2019-06-04 | Eaat2 activators and methods of using thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL279199A IL279199A (en) | 2021-01-31 |
| IL279199B1 true IL279199B1 (en) | 2026-04-01 |
Family
ID=68771005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL279199A IL279199B1 (en) | 2018-06-04 | 2019-06-04 | EAAT2 activators and methods of using them |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11702403B2 (https=) |
| EP (2) | EP4685140A1 (https=) |
| JP (2) | JP2021527636A (https=) |
| CN (1) | CN112533601B (https=) |
| AU (1) | AU2019282231B2 (https=) |
| CA (1) | CA3102762A1 (https=) |
| ES (1) | ES3041367T3 (https=) |
| IL (1) | IL279199B1 (https=) |
| WO (1) | WO2019236625A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3877376T3 (da) | 2018-11-06 | 2023-10-02 | Edgewise Therapeutics Inc | Pyridazinonforbindelser og anvendelser deraf |
| CA3118908A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| AU2019374812B2 (en) | 2018-11-06 | 2025-03-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CN113939295B (zh) * | 2019-03-20 | 2025-05-16 | 金翅雀生物公司 | 哒嗪酮及其使用方法 |
| EP4149621B1 (en) * | 2020-05-13 | 2024-10-30 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4397854A (en) * | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| US20070197536A1 (en) * | 2003-11-10 | 2007-08-23 | Vittorio Dal Piaz | Pyridazin-3(2)-one derivatives and their use as pde4 inhibitors |
| WO2008103277A2 (en) * | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| EP2196465A1 (en) * | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| WO2014032398A1 (zh) * | 2012-08-28 | 2014-03-06 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及其用途 |
| US20140303174A1 (en) * | 2011-08-02 | 2014-10-09 | The Brigham And Women S Hospital, Inc. | Pyridazine derivatives as EAAT2 Activators |
| US20150361100A1 (en) * | 2014-06-17 | 2015-12-17 | Chiesi Farmaceutici S.P.A. | Indolizine derivatives as phoshoinositide 3-kinases inhibitors |
| WO2017123991A1 (en) * | 2016-01-15 | 2017-07-20 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as eaat2 activators |
| WO2018081378A1 (en) * | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260756A (en) * | 1979-11-15 | 1981-04-07 | American Cyanamid Company | 6- And 8-heteroaryl-1,2,4-triazolo[4,3-b]pyridazines |
| US4404203A (en) * | 1981-05-14 | 1983-09-13 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| AU691673B2 (en) * | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
| CA2742411A1 (en) * | 2000-09-18 | 2002-03-21 | Eisai R&D Management Co., Ltd. | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations |
| AUPR606401A0 (en) * | 2001-07-02 | 2001-07-26 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| JP2003313169A (ja) * | 2002-04-19 | 2003-11-06 | Otsuka Chemical Holdings Co Ltd | ４，４−ジフルオロ−３−ブテニル化合物及び農園芸用殺虫・殺ダニ剤 |
| JP4890439B2 (ja) * | 2005-03-07 | 2012-03-07 | 杏林製薬株式会社 | ピラゾロピリジン−４−イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤 |
| US8426412B2 (en) | 2008-04-08 | 2013-04-23 | Dow Agrosciences, Llc. | 2-alkynyl-6-pyridin-2-yl-pyridazinones, 2-alkynyl-6-pyridin-2-yl-dihydropyridazinones, 2-alkynyl-6-pyrimidin-2-yl-pyridazinones and 2-alkynyl-6-pyrimidin-2-yl-dihydropyridazinones and their use as fungicides |
| AU2013365926B9 (en) * | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| EP2953944B1 (en) * | 2013-02-07 | 2017-04-26 | Merck Patent GmbH | Pyridazinone-amides derivatives |
| LT2953952T (lt) * | 2013-02-07 | 2017-08-25 | Merck Patent Gmbh | Makrocikliniai piridazinono dariniai |
| CN106467495A (zh) * | 2015-08-19 | 2017-03-01 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及用途 |
-
2019
- 2019-06-04 EP EP25194190.2A patent/EP4685140A1/en active Pending
- 2019-06-04 CN CN201980052147.6A patent/CN112533601B/zh active Active
- 2019-06-04 JP JP2020567510A patent/JP2021527636A/ja active Pending
- 2019-06-04 IL IL279199A patent/IL279199B1/en unknown
- 2019-06-04 EP EP19815032.8A patent/EP3801528B1/en active Active
- 2019-06-04 AU AU2019282231A patent/AU2019282231B2/en active Active
- 2019-06-04 US US16/972,311 patent/US11702403B2/en active Active
- 2019-06-04 WO PCT/US2019/035452 patent/WO2019236625A1/en not_active Ceased
- 2019-06-04 ES ES19815032T patent/ES3041367T3/es active Active
- 2019-06-04 CA CA3102762A patent/CA3102762A1/en active Pending
-
2022
- 2022-10-04 US US17/959,654 patent/US12286420B2/en active Active
-
2023
- 2023-07-18 US US18/354,330 patent/US20240208936A1/en active Pending
-
2024
- 2024-08-09 JP JP2024133796A patent/JP7794910B2/ja active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4397854A (en) * | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| US20070197536A1 (en) * | 2003-11-10 | 2007-08-23 | Vittorio Dal Piaz | Pyridazin-3(2)-one derivatives and their use as pde4 inhibitors |
| WO2008103277A2 (en) * | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| EP2196465A1 (en) * | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| US20140303174A1 (en) * | 2011-08-02 | 2014-10-09 | The Brigham And Women S Hospital, Inc. | Pyridazine derivatives as EAAT2 Activators |
| WO2014032398A1 (zh) * | 2012-08-28 | 2014-03-06 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及其用途 |
| US20150361100A1 (en) * | 2014-06-17 | 2015-12-17 | Chiesi Farmaceutici S.P.A. | Indolizine derivatives as phoshoinositide 3-kinases inhibitors |
| WO2017123991A1 (en) * | 2016-01-15 | 2017-07-20 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as eaat2 activators |
| WO2018081378A1 (en) * | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
Non-Patent Citations (6)
| Title |
|---|
| HARDING RACHEL J. ET AL:, SMALL MOLECULE ANTAGONISTS OF THEINTERACTION BETWEEN THE HISTONE DEACETYLASE 6 ZINC-FINGER DOMAIN ANDUBIQUITIN, 27 October 2017 (2017-10-27) * |
| IBRAHIM TAMER H. ET AL:, SYNTHESIS OF SOME NOVEL 2,6-DISUBSTITUTEDPYRIDAZIN-3(2 H )-ONE DERIVATIVES AS ANALGESIC, ANTI-INFLAMMATORY, ANDNON-ULCEROGENIC AGENTS : NOVEL 2,6-DISUBSTITUTED PYRIDAZIN-3(2 H )-ONEDERIVATIVES, 9 August 2017 (2017-08-09) * |
| MASAHISA YAMAGUSHI:, NOVEL ANTIASTHMATIC AGENTS WITH DUAL ACTIVITIES OFTHROMBOXANE, 1 January 1994 (1994-01-01) * |
| MATYUS P ET AL:, SYNTHESIS, ANTIHYPERTENSIVE AND @A-ADRENOCEPTORACTIVITY OF NOVEL 2-AMINOALKYL-3(2H)-PYRIDAZINONES, 1 March 1992 (1992-03-01) * |
| REFAAT HANAN MET AL:, SYNTHESIS AND ANTI-INFLAMMATORY ACTIVITY OFCERTAIN PIPERAZINYLTHIENYLPYRIDAZINE DERIVATIVES, 1 July 2007 (2007-07-01) * |
| STRAPPAGHETTI G ET AL:, SYNTHESIS AND BIOLOGICAL AFFINITY OF NEWIMIDAZO- AND INDOL-ARYLPIPERAZINE DERIVATIVES: FURTHER VALIDATION OF APHARMACOPHORE MODEL FOR @A" 1-ADRENOCEPTOR ANTAGONISTS, 15 September 2008 (2008-09-15) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024160326A (ja) | 2024-11-13 |
| US12286420B2 (en) | 2025-04-29 |
| US20210171497A1 (en) | 2021-06-10 |
| US20230138663A1 (en) | 2023-05-04 |
| ES3041367T3 (en) | 2025-11-11 |
| WO2019236625A1 (en) | 2019-12-12 |
| IL279199A (en) | 2021-01-31 |
| JP7794910B2 (ja) | 2026-01-06 |
| CN112533601A (zh) | 2021-03-19 |
| EP4685140A1 (en) | 2026-01-28 |
| AU2019282231A1 (en) | 2021-01-14 |
| US20240208936A1 (en) | 2024-06-27 |
| US11702403B2 (en) | 2023-07-18 |
| CN112533601B (zh) | 2024-08-16 |
| JP2021527636A (ja) | 2021-10-14 |
| AU2019282231B2 (en) | 2025-04-17 |
| EP3801528A1 (en) | 2021-04-14 |
| EP3801528A4 (en) | 2022-03-09 |
| EP3801528B1 (en) | 2025-08-06 |
| CA3102762A1 (en) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276731A (en) | Antibodies against CD73 and methods of using them | |
| IL278821A (en) | Anti-SIRPA antibodies and methods of using them | |
| ZA201906730B (en) | Anti-trem2 antibodies and methods of use thereof | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| HUE062927T2 (hu) | Anti-TIGIT ellenanyagok és alkalmazási eljárásaik | |
| SG11202002889TA (en) | Structurally-colored articles and methods of making and using structurally-colored articles | |
| ZA202300348B (en) | Anti-sortilin antibodies and methods of use thereof | |
| IL273402A (en) | Antibodies against human leukocyte antigens type A2 and methods of using them | |
| IL280709A (en) | Converted indoles and methods of using them | |
| IL279648A (en) | Anti-SIRP-in-cell 1 antibodies and methods of using them | |
| IL279199A (en) | EAAT2 activators and methods of using them | |
| IL287282A (en) | Anti-mertk antibodies and methods of using them | |
| IL277212A (en) | Anti-KLK5 antibodies and methods of use | |
| IL274221A (en) | Antibodies to ANTI-APOC3 and methods of use | |
| IL280338A (en) | Anti-SIGLEC-5 antibodies and methods of using them | |
| IL283884A (en) | Antibodies against il-36 and methods of using them | |
| IL268568A (en) | TRAILshort antibody and methods of use | |
| IL279227A (en) | Anti-SIGLEC-7 antibodies and methods of using them | |
| IL276053A (en) | Therapeutic Gard and methods of its use | |
| IL288886A (en) | Antibodies and methods of use | |
| ZA202002144B (en) | Antibodies and methods of use | |
| GB2574223B (en) | Adhesives and methods of forming adhesives |